Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
BOWIE, Md., March 29, 2017 -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based models across the healthcare ecosystem, today announced it has entered into an agreement with Amgen, one of the world's leading independent biotechnology companies and leader in instituting innovative, value-based contracts across its product portfolio to better manage healthcare costs and enable access to therapeutic solutions that deliver value to patients, payers, and providers. Under the agreement, Inovalon and Avalere Health, an Inovalon Company, will deploy its data, analytics capabilities, and subject matter expertise with Outcomes Based Contracts (OBCs) to support further development of OBCs based on the value of Amgen’s products.
The agreement will focus specifically on rheumatoid arthritis (RA), a chronic, high-cost autoimmune disease affecting more than two million Americans. As the healthcare landscape continues to rapidly transform from fee-for-service and volume-based models to value and outcomes-based models, OBCs have become increasingly prevalent in the marketplace.
About Inovalon
Inovalon’s Outcomes-Based Contracting Platform supports the creation, deployment and management of value-based contracts between payers and life sciences companies through data aggregation and management, predictive analytics, data-driven patient and provider engagement platforms, and data reporting capabilities.
Inovalon is a leading technology company providing cloud-based platforms empowering a data-driven transformation from volume-based to value-based models throughout the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and industry-leading subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, Inovalon’s unique achievement of value is delivered through the effective progression of “Turning Data into Insight, and Insight into Action®.” Providing technology that supports nearly 500 healthcare organizations, Inovalon’s platforms are informed by data pertaining to more than 848,000 physicians, 371,000 clinical facilities, and more than 150 million Americans. For more information, visit www.inovalon.com.
Contact: Inovalon Kim E. Collins Phone: 301-809-4000 x1473 [email protected] George Price (Investors) Phone: 301-809-4000 x1190 [email protected]
